glp 1 gcgr dual agonist Design of novel Xenopus GLP-1-based glucagon-like peptide (GLP-1)/glucagon receptor agonists Structural analysis of the dual

Summary GLP-1 RAs offer a multifaceted therapeutic strategy in PD, targeting both central neurodegenerative processes and peripheral metabolic dysfunction

Purpose of Review This review explores the role of GLP-1 receptor agonists (GLP-1 RAs) in addressing metabolic dysfunction and neurodegeneration in Parkinsons disease (PD), focusing on body weight regulation and neuroprotection

New research suggests that switching to a maintenance dose of GLP-1 medication could help lock in weight loss.

(BPT) At just 30 years old, Gabby weighed 299 pounds and was prediabetic

A randomized study found that holding one preprocedure dose of GLP-1 therapy reduced clinically significant residual gastric volume during EGD.